Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 330

1.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 1;6(5). pii: e591. doi: 10.1212/NXI.0000000000000591. Print 2019 Sep.

2.

Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority.

Romano S, Ferraldeschi M, Bagnato F, Mechelli R, Morena E, Caldano M, Buscarinu MC, Fornasiero A, Frontoni M, Nociti V, Mirabella M, Mayer F, Bertolotto A, Pozzilli C, Vanacore N, Salvetti M, Ristori G.

Front Neurol. 2019 Jul 16;10:695. doi: 10.3389/fneur.2019.00695. eCollection 2019.

3.

The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).

Grimaldi AE, De Giglio L, Haggiag S, Bianco A, Cortese A, Crisafulli SG, Monteleone F, Marfia G, Prosperini L, Galgani S, Mirabella M, Centonze D, Pozzilli C, Castelli L.

PLoS One. 2019 Jul 30;14(7):e0219670. doi: 10.1371/journal.pone.0219670. eCollection 2019.

4.

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.

Neurol Neuroimmunol Neuroinflamm. 2019 Jul 1;6(5):e591. doi: 10.1212/NXI.0000000000000591. eCollection 2019 Sep.

5.

Effect of dalfampridine on information processing speed impairment in multiple sclerosis.

De Giglio L, De Luca F, Gurreri F, Ferrante I, Prosperini L, Borriello G, Quartuccio E, Gasperini C, Pozzilli C.

Neurology. 2019 Aug 20;93(8):e733-e746. doi: 10.1212/WNL.0000000000007970. Epub 2019 Jul 22.

PMID:
31331968
6.

Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis.

De Giglio L, Grimaldi AE, Fubelli F, Marinelli F, Pozzilli C.

Expert Rev Neurother. 2019 May;19(5):417-429. doi: 10.1080/14737175.2019.1610393. Epub 2019 May 16.

PMID:
31094239
7.

Advances in spinal cord imaging in multiple sclerosis.

Moccia M, Ruggieri S, Ianniello A, Toosy A, Pozzilli C, Ciccarelli O.

Ther Adv Neurol Disord. 2019 Apr 22;12:1756286419840593. doi: 10.1177/1756286419840593. eCollection 2019. Review.

8.

Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis.

Petsas N, De Giglio L, González-Quintanilla V, Giuliani M, De Angelis F, Tona F, Carmellini M, Mainero C, Pozzilli C, Pantano P.

Front Neurol. 2019 Mar 22;10:153. doi: 10.3389/fneur.2019.00153. eCollection 2019.

9.

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Gasperini C, Prosperini L, Tintoré M, Sormani MP, Filippi M, Rio J, Palace J, Rocca MA, Ciccarelli O, Barkhof F, Sastre-Garriga J, Vrenken H, Frederiksen JL, Yousry TA, Enzinger C, Rovira A, Kappos L, Pozzilli C, Montalban X, De Stefano N; and the MAGNIMS Study Group.

Neurology. 2019 Jan 22;92(4):180-192. doi: 10.1212/WNL.0000000000006810. Epub 2018 Dec 26. Review.

10.

Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.

D'Amico E, Zanghì A, Sciandra M, Borriello G, Callari G, Gallo A, Salemi G, Cottone S, Buccafusca M, Valentino P, Bossio RB, Grimaldi LME, Pozzilli C, Tedeschi G, Zappia M, Patti F.

J Neurol. 2019 Feb;266(2):411-416. doi: 10.1007/s00415-018-9144-9. Epub 2018 Dec 4.

PMID:
30515629
11.

Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online.

Lavorgna L, Borriello G, Esposito S, Abbadessa G, Capuano R, De Giglio L, Logoteta A, Pozzilli C, Tedeschi G, Bonavita S.

Mult Scler Relat Disord. 2019 Jan;27:239-246. doi: 10.1016/j.msard.2018.10.113. Epub 2018 Nov 5.

PMID:
30419509
12.

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.

Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdič J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T.

Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803248. doi: 10.1177/1756286418803248. eCollection 2018. Review.

13.

Relation between functional connectivity and disability in multiple sclerosis: a non-linear model.

Tommasin S, De Giglio L, Ruggieri S, Petsas N, Giannì C, Pozzilli C, Pantano P.

J Neurol. 2018 Dec;265(12):2881-2892. doi: 10.1007/s00415-018-9075-5. Epub 2018 Oct 1.

PMID:
30276520
14.

Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience.

D'Amico E, Zanghì A, Callari G, Borriello G, Gallo A, Graziano G, Valentino P, Buccafusca M, Cottone S, Salemi G, Ragonese P, Bossio RB, Docimo R, Grimaldi LME, Pozzilli C, Tedeschi G, Zappia M, Patti F.

Ther Adv Neurol Disord. 2018 Sep 10;11:1756286418796404. doi: 10.1177/1756286418796404. eCollection 2018.

15.

2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.

Gaetani L, Prosperini L, Mancini A, Eusebi P, Cerri MC, Pozzilli C, Calabresi P, Sarchielli P, Di Filippo M.

J Neurol. 2018 Nov;265(11):2684-2687. doi: 10.1007/s00415-018-9048-8. Epub 2018 Sep 8.

PMID:
30196327
16.

Predicting the profile of increasing disability in multiple sclerosis.

Tomassini V, Fanelli F, Prosperini L, Cerqua R, Cavalla P, Pozzilli C.

Mult Scler. 2019 Aug;25(9):1306-1315. doi: 10.1177/1352458518790397. Epub 2018 Aug 2.

PMID:
30070597
17.

Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study.

Mirabella M, Prosperini L, Lucchini M, Boffa L, Borriello G, Buscarinu MC, Centonze D, Cortese A, De Fino C, De Giglio L, Elia G, Fantozzi R, Ferraro E, Francia A, Galgani S, Gasperini C, Haggiag S, Landi D, Marfia GA, Millefiorini E, Monteleone F, Nociti V, Salvetti M, Sgarlata E, Pozzilli C.

CNS Drugs. 2018 Oct;32(10):963-970. doi: 10.1007/s40263-018-0543-3.

PMID:
30022464
18.

Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis.

Landi D, Ragonese P, Prosperini L, Nociti V, Haggiag S, Cortese A, Fantozzi R, Pontecorvo S, Ferraro E, Buscarinu MC, Mataluni G, Monteleone F, Salvetti M, Di Battista G, Francia A, Millefiorini E, Gasperini C, Mirabella M, Salemi G, Boffa L, Pozzilli C, Centonze D, Marfia GA.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1272-1278. doi: 10.1136/jnnp-2018-318468. Epub 2018 Jul 3.

PMID:
29970387
19.

Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study.

Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M.

Neurology. 2018 Jul 10;91(2):e153-e161. doi: 10.1212/WNL.0000000000005772. Epub 2018 Jun 6.

PMID:
29875218
20.

Balance worsening associated with nabiximols in multiple sclerosis.

Castelli L, Prosperini L, Pozzilli C.

Mult Scler. 2019 Jan;25(1):113-117. doi: 10.1177/1352458518765649. Epub 2018 Mar 13.

PMID:
29533137
21.

The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis.

Farcomeni A, Cortese A, Sgarlata E, Alunni Fegatelli D, Marfia GA, Buttari F, Mirabella M, De Fino C, Prosperini L, Pozzilli C, Grasso MG, Iasevoli L, Di Battista G, Millefiorini E.

Neuroepidemiology. 2018;50(3-4):105-110. doi: 10.1159/000487005. Epub 2018 Mar 2.

PMID:
29502114
22.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7.

PMID:
29438046
23.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7.

PMID:
29438041
24.

Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Giovannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2018 May;25(5):739-746. doi: 10.1111/ene.13581. Epub 2018 Feb 28.

PMID:
29356206
25.

Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G.

Neurol Sci. 2018 Feb;39(2):395. doi: 10.1007/s10072-017-3226-9.

PMID:
29280018
26.

Role of Cerebellar Dentate Functional Connectivity in Balance Deficits in Patients with Multiple Sclerosis.

Tona F, De Giglio L, Petsas N, Sbardella E, Prosperini L, Upadhyay N, Giannì C, Pozzilli C, Pantano P.

Radiology. 2018 Apr;287(1):267-275. doi: 10.1148/radiol.2017170311. Epub 2017 Dec 22.

PMID:
29272214
27.

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).

Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P, Centonze D, Pozzilli C, Saccà F, Bergh FT, Bartezaghi M, Turrini R, Filippi M; Golden Study Group.

J Neurol. 2017 Dec;264(12):2436-2449. doi: 10.1007/s00415-017-8642-5. Epub 2017 Oct 23.

28.

The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study.

Pappalardo A, Chisari CG, Montanari E, Pesci I, Borriello G, Pozzilli C, D'Amico E, Patti F.

Mult Scler Relat Disord. 2017 Oct;17:154-171. doi: 10.1016/j.msard.2017.07.022. Epub 2017 Jul 28.

PMID:
29055451
29.

Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy.

Rossi F, Prosperini L, De Rossi N, Capra R, Rivanera D, Li X, Cinque P, Passeri L, Pozzilli C, Viscidi R.

Viral Immunol. 2017 Oct;30(8):622-626. doi: 10.1089/vim.2017.0039. Epub 2017 Aug 24.

PMID:
28836899
30.

Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy.

Colais P, Agabiti N, Davoli M, Buttari F, Centonze D, De Fino C, Di Folco M, Filippini G, Francia A, Galgani S, Gasperini C, Giuliani M, Mirabella M, Nociti V, Pozzilli C, Bargagli A; Multiple Sclerosis Study Group, Lazio Region.

Neuroepidemiology. 2017;48(3-4):171-178. doi: 10.1159/000479515. Epub 2017 Aug 9.

PMID:
28793295
31.

Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Amato MP, Bertolotto A, Brunelli R, Cavalla P, Goretti B, Marrosu MG, Patti F, Pozzilli C, Provinciali L, Rizzo N, Strobelt N, Tedeschi G, Trojano M, Comi G.

Neurol Sci. 2017 Oct;38(10):1849-1858. doi: 10.1007/s10072-017-3081-8. Epub 2017 Aug 2. Erratum in: Neurol Sci. 2017 Dec 26;:.

PMID:
28770366
32.

Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study.

Latino P, Castelli L, Prosperini L, Marchetti MR, Pozzilli C, Giovannelli M.

Neurol Sci. 2017 Oct;38(10):1841-1848. doi: 10.1007/s10072-017-3078-3. Epub 2017 Aug 1.

PMID:
28766025
33.

High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline.

Gaetani L, Fanelli F, Riccucci I, Eusebi P, Sarchielli P, Pozzilli C, Calabresi P, Prosperini L, Di Filippo M.

J Neurol Sci. 2017 Aug 15;379:236-240. doi: 10.1016/j.jns.2017.06.008. Epub 2017 Jun 9.

PMID:
28716249
34.

Prognostic indicators in pediatric clinically isolated syndrome.

Iaffaldano P, Simone M, Lucisano G, Ghezzi A, Coniglio G, Brescia Morra V, Salemi G, Patti F, Lugaresi A, Izquierdo G, Bergamaschi R, Cabrera-Gomez JA, Pozzilli C, Millefiorini E, Alroughani R, Boz C, Pucci E, Zimatore GB, Sola P, Lus G, Maimone D, Avolio C, Cocco E, Sajedi SA, Costantino G, Duquette P, Shaygannejad V, Petersen T, Fernández Bolaños R, Paolicelli D, Tortorella C, Spelman T, Margari L, Amato MP, Comi G, Butzkueven H, Trojano M; Italian iMedWeb Registry and the MSBase Registry.

Ann Neurol. 2017 May;81(5):729-739. doi: 10.1002/ana.24938.

PMID:
28439957
35.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236. Epub 2017 Jan 31.

PMID:
28139062
36.

Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial.

De Giglio L, Marinelli F, Barletta VT, Pagano VA, De Angelis F, Fanelli F, Petsas N, Pantano P, Tomassini V, Pozzilli C.

CNS Drugs. 2017 Feb;31(2):161-168. doi: 10.1007/s40263-016-0401-0.

PMID:
27995531
37.

Extratemporal herpes encephalitis during natalizumab treatment: A case report.

Haggiag S, Prosperini L, Galgani S, Pozzilli C, Pinnetti C.

Mult Scler Relat Disord. 2016 Nov;10:134-136. doi: 10.1016/j.msard.2016.10.002. Epub 2016 Oct 5.

PMID:
27919480
38.

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.

Prosperini L, Saccà F, Cordioli C, Cortese A, Buttari F, Pontecorvo S, Bianco A, Ruggieri S, Haggiag S, Brescia Morra V, Capra R, Centonze D, Di Battista G, Ferraro E, Francia A, Galgani S, Gasperini C, Millefiorini E, Mirabella M, Pozzilli C.

J Neurol. 2017 Feb;264(2):284-294. doi: 10.1007/s00415-016-8343-5. Epub 2016 Nov 22.

PMID:
27878443
39.

Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis.

De Giglio L, Upadhyay N, De Luca F, Prosperini L, Tona F, Petsas N, Pozzilli C, Pantano P.

J Neurol Sci. 2016 Nov 15;370:211-213. doi: 10.1016/j.jns.2016.09.041. Epub 2016 Sep 22. No abstract available.

PMID:
27772761
40.

Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.

Laroni A, Brogi D, Brescia Morra V, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL.

Neurol Sci. 2017 Jan;38(1):53-59. doi: 10.1007/s10072-016-2701-z. Epub 2016 Oct 18.

PMID:
27757552
41.

A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.

Galassi S, Prosperini L, Logoteta A, Hirsch MN, Fanelli F, De Giglio L, Pozzilli C.

Mult Scler Relat Disord. 2016 Jul;8:99-106. doi: 10.1016/j.msard.2016.05.012. Epub 2016 May 17.

PMID:
27456883
42.

Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis.

Tocci G, Giuliani M, Canichella F, Timpano J, Presta V, Francia P, Musumeci MB, Fubelli F, Pozzilli C, Volpe M, Ferrucci A.

Int J Cardiol. 2016 Oct 15;221:881-5. doi: 10.1016/j.ijcard.2016.07.134. Epub 2016 Jul 9.

PMID:
27434365
43.

Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features.

Sbardella E, Upadhyay N, Tona F, Prosperini L, De Giglio L, Petsas N, Pozzilli C, Pantano P.

Mult Scler. 2017 Apr;23(4):546-555. doi: 10.1177/1352458516657438. Epub 2016 Jul 18.

PMID:
27411700
44.

The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.

D'Amico E, Leone C, Graziano G, Amato MP, Bergamaschi R, Cavalla P, Coniglio G, Di Battista G, Ferrò MT, Granella F, Granieri E, Lugaresi A, Lus G, Millefiorini E, Pozzilli C, Tedeschi G, Zappia M, Comi G, Trojano M, Lepore V, Patti F.

PLoS One. 2016 Jun 27;11(6):e0157721. doi: 10.1371/journal.pone.0157721. eCollection 2016.

45.

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Sormani MP, Gasperini C, Romeo M, Rio J, Calabrese M, Cocco E, Enzingher C, Fazekas F, Filippi M, Gallo A, Kappos L, Marrosu MG, Martinelli V, Prosperini L, Rocca MA, Rovira A, Sprenger T, Stromillo ML, Tedeschi G, Tintorè M, Tortorella C, Trojano M, Montalban X, Pozzilli C, Comi G, De Stefano N; MAGNIMS study group.

Neurology. 2016 Jul 12;87(2):134-40. doi: 10.1212/WNL.0000000000002830. Epub 2016 Jun 15.

PMID:
27306626
46.

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study.

Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, Havrdova E, MacManus DG, Yousry TA, Pozzilli C, Selmaj K, Sweetser MT, Zhang R, Yang M, Potts J, Novas M, Miller DH, Kurukulasuriya NC, Fox RJ, Phillips TJ.

Mult Scler. 2017 Feb;23(2):253-265. doi: 10.1177/1352458516649037. Epub 2016 Jul 11.

47.

A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.

Truini A, Prosperini L, Calistri V, Fiorelli M, Pozzilli C, Millefiorini E, Frontoni M, Cortese A, Caramia F, Cruccu G.

Neurology. 2016 May 31;86(22):2094-9. doi: 10.1212/WNL.0000000000002720. Epub 2016 May 4.

PMID:
27164695
48.

Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.

Patti F, Messina S, Solaro C, Amato MP, Bergamaschi R, Bonavita S, Bruno Bossio R, Brescia Morra V, Costantino GF, Cavalla P, Centonze D, Comi G, Cottone S, Danni M, Francia A, Gajofatto A, Gasperini C, Ghezzi A, Iudice A, Lus G, Maniscalco GT, Marrosu MG, Matta M, Mirabella M, Montanari E, Pozzilli C, Rovaris M, Sessa E, Spitaleri D, Trojano M, Valentino P, Zappia M; SA.FE. study group.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):944-51. doi: 10.1136/jnnp-2015-312591. Epub 2016 May 9.

49.

Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.

Prosperini L, Fanelli F, Pozzilli C.

J Neurol Sci. 2016 May 15;364:145-7. doi: 10.1016/j.jns.2016.03.025. Epub 2016 Mar 16.

PMID:
27084235
50.

The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence.

Tomassini V, d'Ambrosio A, Petsas N, Wise RG, Sbardella E, Allen M, Tona F, Fanelli F, Foster C, Carnì M, Gallo A, Pantano P, Pozzilli C.

Hum Brain Mapp. 2016 Jul;37(7):2431-45. doi: 10.1002/hbm.23184. Epub 2016 Mar 18.

Supplemental Content

Loading ...
Support Center